Search results for "Interleukin-1beta"

showing 10 items of 114 documents

Anti-Inflammatory and Cytoprotective Effect of Plant Sterol and Galactooligosaccharides-Enriched Beverages in Caco-2 Cells

2019

Plant sterol (PS) (1 g/100 mL) enriched milk-based fruit beverages with or without galactooligosaccharides (GOS) (1.8 g/100 mL) were used in differentiated Caco-2 cells. Their potential cytopreventive effect against oxidative stress induced by cholesterol oxidation products (COPs) and their anti-inflammatory properties were evaluated. Preincubation (24 h) with bioaccessible fractions from beverages without and with GOS (MfB and MfB-G) completely prevented the COPs (60 μM/4 h) induced oxidative stress independent to GOS presence with exception to calcium influx and GSH content, where a partial protective effect was observed. Besides, MfB produced a significant (p < 0.05) reduction of IL-8 (4…

0106 biological sciencesAntioxidantmedicine.drug_classmedicine.medical_treatmentInterleukin-1betaAnti-Inflammatory AgentsOligosaccharidesChromosomal translocationProtective Agentsmedicine.disease_cause01 natural sciencesAnti-inflammatoryBeverageschemistry.chemical_compoundmedicineHumansFood scienceCholesterol010401 analytical chemistryTranscription Factor RelAPhytosterolsGeneral ChemistryGlutathionePlant sterol0104 chemical sciencesOxidative StresschemistryCytoprotectionCaco-2Caco-2 CellsGeneral Agricultural and Biological SciencesOxidative stress010606 plant biology & botanyJournal of Agricultural and Food Chemistry
researchProduct

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Hepatoprotective effects of extracts, fractions and compounds from the stem bark of Pentaclethra macrophylla Benth: Evidence from in vitro and in viv…

2021

Abstract Aim To identify the bioactive hepatoprotective components of the ethanol extract of Pentaclethra macrophylla stem bark using in vitro and in vivo approaches. Methods The bioguided-fractionation of the ethanol extract was based on the substances’ capacity to prevent in vitro, the lipid peroxidation of hepatocytes’ membranes induced by hydrogen peroxide. For the in vivo hepatoprotective test, mice were treated orally with the ethyl acetate (EtOAc) fraction of the ethanol extract at doses of 50 and 75 mg/kg/day for one week and subjected to d -galactosamine/lipopolysaccharide (GaIN/LPS)-induced hepatotoxicity. Blood samples were collected for alanine aminotransferase (ALAT), aspartate…

0301 basic medicineAntioxidantPentaclethra macrophyllaIsolated compoundsmedicine.medical_treatmentInterleukin-1betaLipid peroxidationStructure-activity relationshipsRM1-950AntioxidantsLipid peroxidationSuperoxide dismutase03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineIn vivomedicineAnimalsAspartate AminotransferasesRats WistarPharmacologybiologyTraditional medicinePlant StemsChemistryPlant ExtractsTumor Necrosis Factor-alphaBergeninAlanine TransaminaseFabaceaeGeneral MedicineGlutathioneDisease Models Animal030104 developmental biologyHepatoprotectionLiverCatalase030220 oncology & carcinogenesisbiology.proteinHepatocytesPlant BarkTherapeutics. PharmacologyChemical and Drug Induced Liver InjuryGaIN/LPSHepatoprotectionBiomedicine & Pharmacotherapy
researchProduct

Oleanolic acid improves diet-induced obesity by modulating fat preference and inflammation in mice.

2018

Obesity, triggered by high-fat diet (HFD), is associated to altered gustatory perception of dietary lipids. Oleanolic acid (OLA), a triterpene, has been reported to exert anti-obesity effects in animal models. Hence, we investigated the role of OLA in the modulation of oro-sensory perception of lipids in control and HFD-induced obese mice. As expected, OLA-treated obese mice exhibited a decrease in body, liver, and visceral adipose tissue weights. OLA treatment improved glucose tolerance, insulin level, plasma lipopolysaccharide (LPS), and hepatic cholesterol and triglyceride concentrations. OLA-treated obese mice exhibited higher fat preference compared to untreated obese mice, probably du…

0301 basic medicineCD36 AntigensLipopolysaccharidesmedicine.medical_specialtyCD36medicine.medical_treatmentInterleukin-1betaAdipose tissue030209 endocrinology & metabolismInflammationDiet High-FatDiet MediterraneanWeight GainBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTaste receptorInternal medicinemedicineAnimalsInsulinObesityRNA MessengerOleanolic AcidCarbohydrate-responsive element-binding proteinOleanolic acidInflammationbiologyTriglycerideChemistryInterleukin-6InsulinLipogenesisGeneral MedicineGlucose Tolerance TestTaste BudsMice Inbred C57BL030104 developmental biologyEndocrinologyAdipose TissueLiverbiology.proteinCalciumFemalemedicine.symptomInflammation MediatorsBiochimie
researchProduct

EBI2 Is Highly Expressed in Multiple Sclerosis Lesions and Promotes Early CNS Migration of Encephalitogenic CD4 T Cells

2017

Arrival of encephalitogenic T cells at inflammatory foci represents a critical step in development of experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis. EBI2 and its ligand, 7{alpha},25-OHC, direct immune cell localization in secondary lymphoid organs. CH25H and CYP7B1 hydroxylate cholesterol to 7{alpha},25-OHC. During EAE, we found increased expression of CH25H by microglia and CYP7B1 by CNS-infiltrating immune cells elevating the ligand concentration in the CNS. Two critical pro-inflammatory cytokines, interleukin-23 (IL-23) and interleukin-1 beta (IL-1{beta}), maintained expression of EBI2 in differentiating Th17 cells. In line with this, EBI2 enhan…

0301 basic medicineCD4-Positive T-LymphocytesCentral Nervous SystemMaleGPR183Cancer ResearchEncephalomyelitis Autoimmune ExperimentalOxysterolCentral nervous systemInterleukin-1betaCytochrome P450 Family 7CH25HmicrogliaAutoimmunityBiologymedicine.disease_causemultiple sclerosisInterleukin-23General Biochemistry Genetics and Molecular BiologyAutoimmunityReceptors G-Protein-Coupled03 medical and health sciencesMiceImmune systemCell MovementmedicineAnimalsEBI2lcsh:QH301-705.5MicrogliaEAEMultiple sclerosisExperimental autoimmune encephalomyelitisGPR18325-OHCmedicine.diseaseMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)ImmunologySteroid HydroxylasesTh17 CellsFemaleTh17CNSoxysterolCell Reports
researchProduct

Preventive effects of guanosine on intestinal inflammation in 2, 4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rats

2018

Background: Guanosine, a guanine-based purine, is an extracellular signaling molecule exerting anti-inflammatory and antioxidative effects in several in vivo and in vitro injury models. We aimed to investigate its protective effects on 2, 4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rat. Methods: Rats were divided into five groups and colitis was induced by intracolonic instillation of DNBS (15 mg/rat). Guanosine (4 or 8 mg/kg) was administered for 6 days i.p. starting the day of the colitis induction. Body weight loss, stool consistency, colon weight/length, histological analysis, myeloperoxidase activity (MPO) and pro-inflammatory cytokine levels were assessed. Immunoblotting …

0301 basic medicineDNBS ratColonmedicine.medical_treatmentInterleukin-1betaImmunologyAnti-Inflammatory AgentsGuanosineInflammationPharmacologySettore BIO/09 - FisiologiaInflammatory bowel diseaseAntioxidantsInflammatory bowel disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivomedicineAnimalsPharmacology (medical)Intestinal MucosaRats WistarColitisPurineInflammationPharmacologychemistry.chemical_classificationReactive oxygen speciesGuanosineInterleukin-6Tumor Necrosis Factor-alphaNF-kappa BColitismedicine.diseaseRats030104 developmental biologyCytokinechemistryCytokinesDinitrofluorobenzeneTumor necrosis factor alphamedicine.symptomReactive Oxygen Species030217 neurology & neurosurgeryInflammopharmacology
researchProduct

Neuromodulatory effect of interleukin 1β in the dorsal raphe nucleus on individual differences in aggression

2021

Heightened aggressive behavior is considered as one of the central symptoms of many neuropsychiatric disorders including autism, schizophrenia, and dementia. The consequences of aggression pose a heavy burden on patient’s families, clinicians, and the patients themselves. At the same time, we have limited treatment options for aggression and lack mechanistic insight into the causes of aggression needed to inform new efforts in drug discovery and development. Levels of proinflammatory cytokines in the periphery or cerebrospinal fluid were previously reported to correlate with aggressive traits in humans. However, it is still unknown whether cytokines affect brain circuits to modulate aggress…

0301 basic medicineDorsal Raphe NucleusMaleSerotoninInterleukin-1betaIndividualityArticleProinflammatory cytokine03 medical and health sciencesCellular and Molecular NeuroscienceMice0302 clinical medicineDorsal raphe nucleusdorsal raphe nucleumedicinePremovement neuronal activityAnimalsHumansMolecular BiologyGene knockdownAggressionbusiness.industrymedicine.diseaseAggressionPsychiatry and Mental health030104 developmental biologySchizophreniaForebrainSettore BIO/14 - Farmacologiainterleukin 1βSerotoninmedicine.symptombusinessNeuroscience030217 neurology & neurosurgery
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct

The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes

2018

Background Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients. Objective We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. Method After literature search, the available evidence has bee…

0301 basic medicineInterleukin-1betaInflammationAnakinra; Cardiovascular risk; Diabetes; IL-1β; Pathogenesis; Rheumatoid arthritis; Therapy; PharmacologyType 2 diabetesPathogenesisDiabeteProinflammatory cytokinePathogenesisArthritis Rheumatoid03 medical and health sciencesImmune systemPathogenesiDiabetes mellitusmedicineHumansRheumatoid arthritisRheumatoid arthritiPharmacologyAnakinrabusiness.industryDiabetesAntirheumatic AgentReceptors Interleukin-1General Medicinemedicine.diseaseCardiovascular riskSettore MED/16 - Reumatologia030104 developmental biologyAnakinraDiabetes Mellitus Type 2IL-1βRheumatoid arthritisAntirheumatic AgentsImmunologyTherapymedicine.symptombusinessmedicine.drugHuman
researchProduct

Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.

2019

Background & Aims Increased hepatocyte death contributes to the pathology of acute and chronic liver diseases. However, the role of hepatocyte pyroptosis and extracellular inflammasome release in liver disease is unknown. Methods We used primary mouse and human hepatocytes, hepatocyte-specific leucine 351 to proline Nlrp3KICreA mice, and GsdmdKO mice to investigate pyroptotic cell death in hepatocytes and its impact on liver inflammation and damage. Extracellular NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasomes were isolated from mutant NLRP3-YFP HEK cells and internalisation was studied in LX2 and primary human hepatic stellate cells. We also examined a cohort of 154…

0301 basic medicineLiver CirrhosisInflammasomesInterleukin-1betaArticle03 medical and health sciencesLiver diseaseMice0302 clinical medicineMice Inbred NODNon-alcoholic Fatty Liver DiseaseNLR Family Pyrin Domain-Containing 3 ProteinmedicineHepatic Stellate CellsPyroptosisAnimalsHumansLiver injuryHepatologyChemistryFatty liverCaspase 1PyroptosisInflammasomemedicine.disease3. Good healthCell biology030104 developmental biologymedicine.anatomical_structureHepatocyteHepatic stellate cellHepatocytesProtein Translocation Systems030211 gastroenterology & hepatologySteatohepatitisReactive Oxygen Speciesmedicine.drugJournal of hepatology
researchProduct